892 related articles for article (PubMed ID: 19013787)
1. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency.
Bottomley A; Jones D; Claassens L
Eur J Cancer; 2009 Feb; 45(3):347-53. PubMed ID: 19013787
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported outcomes supporting anticancer product approvals.
Rock EP; Kennedy DL; Furness MH; Pierce WF; Pazdur R; Burke LB
J Clin Oncol; 2007 Nov; 25(32):5094-9. PubMed ID: 17991927
[TBL] [Abstract][Full Text] [Related]
3. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
4. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
5. Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labels.
Willke RJ; Burke LB; Erickson P
Control Clin Trials; 2004 Dec; 25(6):535-52. PubMed ID: 15588741
[TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges.
Hao Y
Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):407-20. PubMed ID: 20715918
[TBL] [Abstract][Full Text] [Related]
7. Current status of patient-reported outcomes in industry-sponsored oncology clinical trials and product labels.
Gondek K; Sagnier PP; Gilchrist K; Woolley JM
J Clin Oncol; 2007 Nov; 25(32):5087-93. PubMed ID: 17991926
[TBL] [Abstract][Full Text] [Related]
8. Lost in translation: differences in antimicrobial indication approval policies between the United States and Europe.
Pappas G; Ierodiakonou V; Falagas ME
Clin Ther; 2009 Jul; 31(7):1595-603. PubMed ID: 19695409
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in cancer: a review of recent research and policy initiatives.
Lipscomb J; Gotay CC; Snyder CF
CA Cancer J Clin; 2007; 57(5):278-300. PubMed ID: 17855485
[TBL] [Abstract][Full Text] [Related]
10. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products.
Rock EP; Scott JA; Kennedy DL; Sridhara R; Pazdur R; Burke LB
J Natl Cancer Inst Monogr; 2007; (37):27-30. PubMed ID: 17951228
[TBL] [Abstract][Full Text] [Related]
11. [New drugs and European procedures of approval. The European Agency for the Evaluation of Medicinal Products' role].
Ainsworth MA
Ugeskr Laeger; 2003 Apr; 165(16):1648-9. PubMed ID: 12756819
[TBL] [Abstract][Full Text] [Related]
12. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
13. FDA guidance on patient reported outcomes.
Speight J; Barendse SM
BMJ; 2010 Jun; 340():c2921. PubMed ID: 20566597
[No Abstract] [Full Text] [Related]
14. Europe learns from US drug mistakes.
Alcorn K
J Int Assoc Physicians AIDS Care; 1996 Mar; 2(3):39. PubMed ID: 11363346
[TBL] [Abstract][Full Text] [Related]
15. A review of patient-reported outcome labels in the United States: 2006 to 2010.
Gnanasakthy A; Mordin M; Clark M; DeMuro C; Fehnel S; Copley-Merriman C
Value Health; 2012 May; 15(3):437-42. PubMed ID: 22583453
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life and other patient-reported outcomes in the European centralized drug regulatory process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003.
Szende A; Leidy NK; Revicki D
Value Health; 2005; 8(5):534-48. PubMed ID: 16176492
[TBL] [Abstract][Full Text] [Related]
17. The Investigators' Brochure: a comparison of the draft international conference on harmonisation guideline with current Food and Drug Administration requirements.
Cocchetto DM
Qual Assur; 1995 Dec; 4(4):240-6. PubMed ID: 8890349
[TBL] [Abstract][Full Text] [Related]
18. Reasons for rejection of patient-reported outcome label claims: a compilation based on a review of patient-reported outcome use among new molecular entities and biologic license applications, 2006-2010.
DeMuro C; Clark M; Mordin M; Fehnel S; Copley-Merriman C; Gnanasakthy A
Value Health; 2012 May; 15(3):443-8. PubMed ID: 22583454
[TBL] [Abstract][Full Text] [Related]
19. Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): searching for standards.
Cleeland CS; Sloan JA;
J Pain Symptom Manage; 2010 Jun; 39(6):1077-85. PubMed ID: 20538189
[TBL] [Abstract][Full Text] [Related]
20. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective.
Chuang-Stein C; Beltangady M
J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
